SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

Add BPTH Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/28/2017 3:29:31 PM - Followers: 36 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug to begin phase II. The patient dosing has begun at trials which will occur at up to 10 sites or more, including MD Anderson, Baylor, New Jersey Hematology Oncolo
gy Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the 8 cohort of phase 1 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. With the completion of the combination safety trials with LDAC and FDA approval, phase 2 has begun and is accepting patients.  This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in mid 2017. A CML combination drug safety study for BP1001 is also expected to be completed by mid 2017.
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.

While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest.  Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:

The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional 10 million dollars the company has $11+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
BPTH is traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:!/4292/presentation/2610

Analyst target price: Maxim $2, Rodman & Renshaw $5, HC Wainwright a buy with a $5.00 target.

Zack's upgraded rating now equals 3 or hold.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#2619   Doesn't appear to be doing much for the 4starman 04/28/17 03:29:31 PM
#2618   That feels like a swift kick right in dmoffat 04/28/17 03:03:00 PM
#2617   Believe or not, Zacks gave this a buy 4starman 04/28/17 12:56:25 PM
#2616   Took me a week but sold the 50,000 iloveu2 04/27/17 12:25:22 AM
#2615   No, SJ you don't disagree. You are saying Gpheart2016 04/26/17 10:18:06 AM
#2614   Pat and GP, I disagree. If the FDA SJSTOCKSHARK 04/26/17 12:14:23 AM
#2613   I agree with this prediction. I don't Pat Torney 04/25/17 12:42:31 PM
#2612   I should never predict stock price as my Gpheart2016 04/25/17 12:11:14 PM
#2611   GP, Perhaps I should have used the word SJSTOCKSHARK 04/25/17 10:44:25 AM
#2610   Yes, I do still have a few shares PStates 04/25/17 10:09:41 AM
#2609   There has always been paper indicating action is PStates 04/25/17 09:38:58 AM
#2608   I have been ready for a class action PStates 04/25/17 09:20:50 AM
#2607   SJ, you would be happy with $12? Gpheart2016 04/24/17 11:48:17 PM
#2606   Optimist, I have repeatedly posted I am a SJSTOCKSHARK 04/24/17 08:47:38 PM
#2605   I don't have the same experience as others wordlender 04/24/17 04:48:23 PM
#2604   Optimist, I'm still holding long, but that doesn't Brettj 04/24/17 03:20:10 PM
#2603   Brettj and Stockshark, cautious optimist 04/24/17 02:59:49 PM
#2602   Word, I agree with Brettj. There is simply SJSTOCKSHARK 04/23/17 09:45:27 PM
#2601   Wordlender, you claim the company doesn't have access Brettj 04/23/17 05:39:47 PM
#2600   Although I am also frustrated and I agree wordlender 04/22/17 08:23:46 PM
#2599   PStates, if your theory is correct all the Snug9 04/21/17 08:05:47 PM
#2598   Optimism is important, especially if you're not going Brettj 04/21/17 12:07:44 PM
#2597   I, too am extremely frustrated. However, we cautious optimist 04/21/17 09:28:44 AM
#2596   I don't think anyone is taking intentional action PStates 04/21/17 07:29:58 AM
#2595   Thanks for your compliments. I too would love PStates 04/21/17 07:25:47 AM
#2594   PStates, it's good to hear from you Gpheart2016 04/20/17 05:10:39 PM
#2593   BPTH has cancer of the leadership brain. BOD PStates 04/20/17 01:14:11 PM
#2592   You are right Iloveu2 and IMO you made Gpheart2016 04/20/17 10:24:40 AM
#2591   It seems something is brewing, hopefully something good. dmoffat 04/19/17 03:32:38 PM
#2590   What's with all he new volume? I iloveu2 04/19/17 01:38:33 PM
#2589   Greed can get the best of anybody if dmoffat 04/17/17 02:11:44 PM
#2588   I like the recent change in pps and Gpheart2016 04/17/17 12:33:28 PM
#2587   Moffat, I continue to fume over the option SJSTOCKSHARK 04/17/17 11:56:47 AM
#2586   Dr. Hayne has direct experience with AML but SJSTOCKSHARK 04/17/17 11:47:45 AM
#2585   So eventually, Ulrich take over as CEO and dmoffat 04/17/17 11:18:50 AM
#2584   Bio-Path Holdings Announces Appointment of Dr. William Hahne Teeds 04/17/17 08:07:50 AM
#2583   Snug, I spent Easter afternoon reading the annual SJSTOCKSHARK 04/16/17 06:23:47 PM
#2582   Snug, If you are correct it is time SJSTOCKSHARK 04/14/17 10:12:18 PM
#2581   Brettj, looking at the annual report it looks Snug9 04/14/17 01:10:39 PM
#2580   Anyone up for a good laugh? From Snug9 04/14/17 01:04:33 PM
#2579   Just woke up and realized what a buying Gpheart2016 04/13/17 02:43:40 PM
#2578   Yeah, in April 2016 there were 1 million wordlender 04/13/17 08:30:22 AM
#2577   So.... Sooo......... True.......................... We can only hope. rktclh 04/12/17 11:37:00 PM
#2576   Baby steps . . . Brettj 04/12/17 10:47:25 PM
#2575   He's still listed as Pres, CEO, CFO rktclh 04/12/17 10:39:52 PM
#2574   Peter no longer listed on BOD or as Brettj 04/12/17 10:11:59 PM
#2573   Peter, Are you honest in your business dealings? tyroneweaver 04/12/17 08:51:43 PM
#2572   Wasatch front scam continues its slide tyroneweaver 04/12/17 08:48:47 PM
#2571   Word, There was less than 1 million shorted SJSTOCKSHARK 04/12/17 08:43:30 PM
#2570   Just an FYI, Peter got paid nearly $456,000 Brettj 04/12/17 08:12:53 PM